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Abstract
Background: The purpose of this study was to evaluate the biodistribution and toxicity of amphotericin B (AmB)
following multiple oral administrations of a novel tropically stable lipid-based formulation (iCo-010).
Methods: BALB/c mice were allocated into six groups: oral iCo-010 twice daily for 5 days in the dose of 20, 10, 5
and 2.5 mg/kg; vehicle control; and intravenous boluses of Fungizone
® 2 mg/kg once daily for 5 days. The animals
were sacrificed 12 h following the last administration and blood and tissues were collected.
Results: The plasma concentrations of AmB were similar to previously reported after administration of iCo-009.
Somewhat lower concentrations of AmB were detected in reticulo-endothelial system in the case of iCo-010 when
compared with iCo-009. The concentration in kidney was higher with iCo-010 than with iCo-009. The creatinine
levels in all oral treatment groups were in a normal range as in the case of iCo-009. Administration of Fungizone
®
resulted in elevated plasma creatinine levels. Histopathology analysis detected no GI, liver or kidney toxicity
following multiple dose oral administration of iCo-010. Fungizone
® treatment induced necrotic changes in hepatic
and kidney tissues.
Conclusions: Given the tropical stability of iCo-010, near identical activity against visceral leishmaniasis and
significant concentrations in target organs this formulation has a potential to become a treatment of choice in
tropical developing countries.
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Findings
Amphotericin B (AmB) is a polyene antibiotic that is
used in treatment of systemic fungal and parasitic infec-
tions. The major limitations of existing AmB therapies
are the toxicity of the drug (mainly to kidneys) and the
need for parenteral administration due to poor oral
bioavailability [1]. Parenteral lipid-based formulations of
AmB such as Abelcet
® and Ambisome
® significantly
decreased the toxicity associated with the treatment.
However, the need to administer the drug intravenously
and high costs associated with these lipid-based formu-
lations are still being serious limitations of the current
treatments, especially in developing countries [2].
Experimental lipid-based parenteral formulations of
AmB based on less expensive ingredients have been
reported [3,4].
Oral lipid-based formulation of AmB (iCo-009) com-
posed of monoglycerides, diglycerides and distearoylpho-
sphatidylethanolamine polyethylene glycol 2000 [5] has
been previously reported to be effective against systemic
fungal infections in rats [5] and against visceral leishma-
niasis in mice [6]. The biodistribution pattern and the lack
of kidney, liver or gastrointestinal toxicity in mice [7] sup-
ported the efficacy data and suggested that this lipid-based
formulation has a promising potential in treating fungal
and parasitic infections. However, the insufficient tropical
temperature stability limited the potential of iCo-009 for
use in developing third-world countries with hot climate.
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countries due to spread of diseases such as leishmaniasis
on one hand and the lack of appropriate infrastructure
and financial struggles that limit the parenteral administra-
tion of amphotericin B on the other hand. Keeping the
challenge of tropical climate stability in mind, a new oral
lipid-based formulation of AmB (iCo-010) composed of
monoglycerides, diglycerides, polyethylene glycol glycer-
ides and D-alpha-tocopheryl polyethylene glycol succinate
[8] has been developed and tested against visceral leishma-
niasis in a murine model. The formulation showed slightly
decreased activity against visceral leishmaniasis comparing
to iCo-009 (but still about 99% inhibition at the highest
dose of 10 mg/kg twice daily (BID) for 5 days) and very
good stability at tropical temperatures [8].
T h ep u r p o s eo ft h ec u r r e n tw o r kw a st oe v a l u a t et h e
tissue distribution and toxicity of AmB following multi-
ple dose oral administration of a novel tropically stable
lipid-based formulation (iCo-010). In addition to tissues
that were examined in our previous work with iCo-009
[7,9], in this study we have added additional organs
(skin, muscle and adipose tissue). An additional novel
aspect of this work was that tissue concentrations of
AmB following multiple intravenous (IV) bolus adminis-
trations of Fungizone
® were also measured and com-
pared to the concentrations obtained after multiple oral
dosing, a head to head comparison that was not done in
our previous works with multiple administrations of
older formulations.
Methods
The lipid-based oral formulation of AmB (iCo-10) was
prepared as recently reported [8]. AmB powder and
1-Amino-4-nitronaphtalene (internal standard) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Fungi-
zone
® (AmB micellular dispersion, Bristol-Myers Squibb,
Montreal, Canada), was purchased from Vancouver
General Hospital pharmacy. All other chemicals were of
analytical reagent grade, and solvents were of HPLC grade.
The use of animals for this study was approved by the
University of British Columbia’s Animal Care Committee
and all experimental protocols conform to the Canadian
Council on Animal Care guidelines. BALB/c female mice
with a body weight of 18-20 g (Charles River Labora-
tories, Wilmington, MA, USA) were used in this work.
Following a one week acclimatization period animals
were allocated into the following groups: oral gavages of
iCo-010 twice daily for 5 days in the dose of 20 mg/kg
(n = 7), 10 mg/kg (n = 6), 5 mg/kg (n = 6) and 2.5 mg/kg
(n = 6); oral gavages of vehicle control of iCo-010 (n = 5);
and intravenous (IV) boluses of Fungizone
® once daily
for 5 days in the dose that was shown to be nephrotoxic
in a previously reported study (2 mg/kg, n = 16) [3]. The
animals were sacrificed 12 h following the last
administration of AmB, blood and tissues were collected
for drug analysis and histopathological evaluation.
Plasma and tissue samples were analyzed for concen-
t r a t i o n so fA m Bb yH P L Ca sp r e v i o u s l yr e p o r t e d[ 7 ] .
Plasma samples were analyzed for creatinine concentra-
tions using previously published validated HPLC method
[10].
Right kidney, a portion of jejunum and a median lobe
of liver were removed and fixated in 10% neutral buf-
fered formalin for histopathological analysis.
Results and Discussion
The concentrations of AmB in plasma and multiple organs
12 hours following the administration of the last dose of
iCo-010 or Fungizone
® are shown in Table 1. The plasma
concentrations following the administration of iCo-010
are similar to previously reported after multiple dose
administration of another lipid-based formulation, iCo-
009 [7]. However, there are considerable differences in tis-
sue distribution pattern. Lower concentrations of AmB are
detected in reticulo-endothelial system organs in the case
of iCo-010 than has been reported previously with iCo-
009 [7]. This is consistent with slightly lower activity of
iCo-010 in a murine model of visceral leishmaniasis [6,8].
However, the marginal reduction in activity comes with
increased tropical stability of iCo-010 [8], which is an
important advantage given the hot climate in areas where
the leishmaniasis is spread and the limited refrigeration
capabilities in these regions. Interestingly, concentrations
in kidney tissues obtained in this study following the
administration of iCo-010 (Table 1) were significantly
higher than after administration of iCo-009 [5]. Although
differences in the rate and extent of intestinal absorption
between iCo-009 and iCo-010 cannot be ruled out at this
moment, opposite direction of changes in reticulo-
endothelial system and in kidney and similar concentra-
tions in plasma and brain suggest that dissimilarity in con-
centrations of AmB in tissues after administration of two
lipid-based formulations is related mostly to differences in
post-absorptive distribution. When concentrations of
AmB in tissues are compared to those obtained in plasma
after the oral administration of iCo-010, it can be seen
that AmB is preferentially accumulated in liver, spleen,
lung and adipose tissues (Table 1). The levels in heart,
brain, skin and skeletal muscle are not statistically signifi-
cantly different from levels observed in plasma. In the
Fungizone
® group a similar pattern of preferential accu-
mulation in reticulo-endothelial and adipose tissues can be
observed. However, due to high variability in this group
only AmB concentrations in liver and spleen tissues were
found to be statistically different from levels in plasma.
The relatively high concentration obtained in adipose
tissues (in iCo-010 and in Fungizone
® groups) suggests
that adipose tissue can create an important depot
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consideration in pharmacokinetic calculations and model-
ing of AmB [11]. The relatively low levels observed in
muscle tissues can still be significant in terms of total
amount of the drug residing in these tissues due to high
mass of muscle tissues in the body. The levels obtained in
skin tissue after administration of iCo-10 or Fungizone
®
were significant, but not different from plasma. The lack
of preferential accumulation in skin suggests that longer
treatment regimens would be needed for treatment of
cutaneous or mucocutaneous forms of leishmaniasis than
for visceral form of the disease. The creatinine levels in all
oral treatment groups (Figure 1) were in a normal range
and similar to previously reported values after administra-
tion of iCo-009 [5]. Administration of IV boluses of Fungi-
zone
® 2 mg/kg resulted in acute toxicity (ten animals (out
of 16) were lost within minutes following one of the dos-
ings). The plasma creatinine levels in six animals in this
group that survived all five administrations reached mild
renal toxicity levels (Figure 1). As with iCo-009 [5] histo-
pathology analysis detected no intestine, liver or kidney
toxicity in this study following multiple dose oral adminis-
tration of iCo-010, including at the highest dose (20 mg/
kg) (data not shown). On the other hand Fungizone
®
treatment induced necrotic changes in hepatic and kidney
tissues identical to those reported in our previous study
[5] (Figure 2A and 2B).
In conclusion, in the current work the biodistrbution
and toxicity of a novel tropically stable oral lipid-based
formulation of AmB (iCo-010) was assessed in a mouse
model. Although the levels in reticulo-endothelial sys-
tem (target organs in treatment of visceral leishmaniasis)
were somewhat lower than with previously described
(tropically unstable) oral formulation of AmB (iCo-009)
[7], the concentrations wer es t i l lw e l la b o v et h eI C 50
(reported to be about 50-100 ng/ml [12,13]) for leishma-
nia organism at all tested doses. These data support the
previously reported near identical activity of iCo-009
and iCo-010 in a murine model of visceral leishmaniasis
[6,8]. The concentrations in kidney tissue following
Table 1 Tissue concentration of amphotericin B (Mean ± SEM; ng/g) in mice 12 hours following the completion of
twice-daily × 5 days treatment course of different doses of oral tropically stable formulation of AmB (iCo-010) or
12 hours following the completion of once daily × 5 days IV treatment course of Fungizone
® 2 mg/kg
iCo-010 20 mg/kg BID for
5 days, n = 7
a
iCo-010 10 mg/kg BID for
5 days, n = 6
b
iCo-010 5 mg/kg BID for
5 days, n = 6
c
iCo-010 2.5 mg/kg BID for
5 days, n = 6
b
Fungizone
®
2 mg/kg QD for 5
days, n = 6
d
Plasma 538 ± 27 418 ± 48 232 ± 22 172 ± 10 791 ± 90
Liver 3494 ± 287 2543 ± 510 836 ± 97 446 ± 44 49794 ± 6993
Spleen 1939 ± 87 1407 ± 120 916 ± 121 342 ± 20 27008 ± 2400
Lung 3179 ± 312 2014 ± 185 1168 ± 307 408 ± 47 7533 ± 1299
Kidney 3685 ± 334 2268 ± 220 813 ± 89 495 ± 31 9100 ± 1140
Heart 366 ± 31 338 ± 41 156 ± 10 84 ± 8 1139 ± 243
Brain 169 ± 6 157 ± 3 112 ± 10 59 ± 5 234 ± 23
Skin 393 ± 45 165 ± 19 116 ± 20 BLQ 420 ± 269
Muscle 26 ± 16 24 ± 8 BLQ BLQ 468 ± 148
Visceral
Fat
2114 ± 512 904 ± 220 471 ± 112 BLQ 3324 ± 654
aAmB concentration in plasma is statistically significantly different from concentration in liver (p < 0.01), spleen (p < 0.01), kidney (p < 0.01), lung (p < 0.01) and
fat tissue (p < 0.01) within the same treatment group (One-way ANOVA followed by Dunnett Multiple Comparisons Test).
bAmB concentration in plasma is statistically significantly different from concentration in liver (p < 0.01), spleen (p < 0.01), kidney (p < 0.01) and lung (p < 0.01)
within the same treatment group (One-way ANOVA followed by Dunnett Multiple Comparisons Test).
cAmB concentration in plasma is statistically significantly different from concentration in liver (p < 0.01), spleen (p < 0.01), kidney (p < 0.05) and lung (p < 0.01)
within the same treatment group (One-way ANOVA followed by Dunnett Multiple Comparisons Test).
dAmB concentration in plasma is statistically significantly different from concentration in liver (p < 0.01) and spleen (p < 0.01) within the same treatment group
(One-way ANOVA followed by Dunnett Multiple Comparisons Test).
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Figure 1 Plasma creatinine concentrations (Mean ± SEM; mg/
dL) in mice 12 hours following the completion of twice-daily ×
5 days treatment course of different doses of iCo-010 (n = 5-6)
or 12 hours following the completion of once daily × 5 days IV
treatment course of Fungizone
® 2 mg/kg (n = 6). Ten (out of
16) animals were lost at different times during the dosing of
Fungizone
® due to acute toxicity associated with this dose.
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reported with iCo-009. Plasma creatinine measurement
and kidney, liver and jejunum histopathology analysis
have not detected any toxicity signs following the
administration of iCo-010.
Taking into consideration the tropical stability of
iCo-010, near identical (to iCo-009) activity against
visceral leishmaniasis and significant concentrations in
target organs this formulation has a potential to
become the treatment of choice in developing coun-
tries where the oral treatment of visceral leishmaniasis
is most needed.
List of abbreviations
AmB: amphotericin B; IV: intravenous; BID: twice daily; QD: once daily
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